Over 300 workers are busy working for the construction of the temporary quarantine center in Quangang district of Quanzhou, East China's Fujian Province.
Bangladesh will be able to produce 5 million doses of Sinopharm's inactivated COVID-19 vaccines monthly, according to a memorandum of understanding signed virtually from Beijing and Dhaka on Aug 16.
In order to enhance its nucleic acid testing capabilities, Yangzhou is building two advanced air-inflated testing labs at Yangzhou International Exhibition Center.
Move demonstrates China's resolve to offer its domestic products as benefit for entire world.
China's inactivated vaccines against COVID-19 are exceptionally agile at tackling emerging variants and domestic vaccine manufacturers are fully prepared to update their shots, health experts and drugmakers have said.
Construction of the refrigeratory's main body of Sinopharm Zhongsheng COVID-19 expansion project for inactivated vaccine in Wuhan, Central China's Hubei Province, was completed on May 10.
A new COVID-19 vaccine developed by China's Sinopharm has recently been approved for clinical trials.
China will start mass COVID-19 vaccinations for people over age 60 after it receives sufficient data from clinical trials on the effectiveness and safety of the vaccines, a senior health official said on March 21.
China will simplify visa applications for many foreign nationals who have been inoculated with Chinese-produced COVID-19 vaccines, the latest step toward normalizing personnel exchanges.
China approved a recombinant protein subunit vaccine against COVID-19 for emergency use on March 17, its developer, the Chinese Academy of Sciences' Institute of Microbiology, said.
China always puts the safety and efficacy of COVID-19 vaccines first, a spokesperson for the annual session of the country's top political advisory body said on March 3.
An adenovirus vector vaccine against COVID-19 by CanSino Biologics is projected to provide protection for two years if a booster shot is administered, said a scientist who played a key role in the vaccine's development.
China approved the registration applications of two domestically developed COVID-19 vaccines with conditions, the National Medical Products Administration said on Feb 25.
China has approved 16 domestically made COVID-19 vaccines for clinical trials, six of which have entered phase 3, according to the latest data from the National Medical Products Administration.
Global coronavirus infections may start to decrease in March with vaccinations and other active epidemic control measures being carried out, prominent respiratory disease expert Zhong Nanshan said on Jan 31.
More than 24 million doses of COVID-19 vaccine have been administered in China, the Chinese Center for Disease Control and Prevention said on Jan 31.
The "Huoyan" laboratory will soon be put into use to fight the COVID-19 pandemic in Harbin.
A total of seven Chinese-made COVID-19 vaccines have entered phase-3 clinical trials, according to an official with the Ministry of Science and Technology (MOST).
A total of 22.77 million doses of COVID-19 vaccine have been administered in China by Jan 26, the National Health Commission said in Beijing on Jan 27.
As of Jan 22, a total of 5.28 million nucleic acid samples have been tested in Shijiazhuang's "Huoyan" laboratory since it was put into use from Jan 8.